Gyre Therapeutics stock: dividend
GYREGyre Therapeutics does not currently pay a dividend; its last payment went ex on 13 Jan 2023. Gyre Therapeutics did not buy back any of its own shares from fiscal 2023 to 2025.
Whether Gyre Therapeutics, Inc. pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 13 Nov 2026
Dividend dates and payments
Anyone holding the stock on the day before the ex-dividend date receives the dividend. Amounts are per share, before tax.
All 2 payments of the last five years
| Ex-dividend date | Dividend per share |
|---|---|
| 13 Jan 2023 | $3.60 |
| 21 Sep 2022 | $21.45 |
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | −$180K | $0 | 89.34M |
| 2024 | −$6.77M | $0 | 85.09M |
| 2023 | $17.31M | $0 | 65.83M |
| 2022 | $5.68M | $0 | 75.69M |
| 2021 | −$84.59M | $0 | 30.64M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
